Biomerica Net Worth
Biomerica Net Worth Breakdown | BMRA |
Biomerica Net Worth Analysis
Biomerica's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Biomerica's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Biomerica's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Biomerica's net worth analysis. One common approach is to calculate Biomerica's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Biomerica's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Biomerica's net worth. This approach calculates the present value of Biomerica's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Biomerica's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Biomerica's net worth. This involves comparing Biomerica's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Biomerica's net worth relative to its peers.
Enterprise Value |
|
To determine if Biomerica is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Biomerica's net worth research are outlined below:
| Biomerica had very high historical volatility over the last 90 days | |
| Biomerica has some characteristics of a very speculative penny stock | |
| Biomerica has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 5.42 M. Net Loss for the year was (5.98 M) with profit before overhead, payroll, taxes, and interest of 446 K. | |
| Biomerica currently holds about 6.08 M in cash with (5.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Biomerica has a poor financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Granahan Investment Management Reduces Stake in Biomerica Inc |
Biomerica uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Biomerica. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Biomerica's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 12th of April 2024 Upcoming Quarterly Report | View | |
| 29th of February 2024 Next Fiscal Quarter End | View |
Know Biomerica's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Biomerica is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Biomerica backward and forwards among themselves. Biomerica's institutional investor refers to the entity that pools money to purchase Biomerica's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Heritage Investors Management Corp | 2024-09-30 | 21 K | Northern Trust Corp | 2024-09-30 | 20.7 K | Penn Capital Management Company Llc | 2024-09-30 | 20.6 K | Two Sigma Securities, Llc | 2024-09-30 | 16.9 K | Raymond James Finl Svs Advisors, Inc. | 2024-09-30 | 14.5 K | Hollencrest Securities, Llc | 2024-09-30 | 11.6 K | Tower Research Capital Llc | 2024-09-30 | 3.9 K | Atlantic Trust Group, Llc | 2024-06-30 | 2.6 K | Bank Of America Corp | 2024-06-30 | 1.5 K | Granahan Investment Management Inc.. | 2024-09-30 | 527.5 K | Acadian Asset Management Llc | 2024-09-30 | 225.4 K |
Follow Biomerica's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.46 M.Market Cap |
|
Project Biomerica's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.66) | (0.63) | |
| Return On Capital Employed | (0.90) | (0.86) | |
| Return On Assets | (0.65) | (0.61) | |
| Return On Equity | (0.91) | (0.86) |
When accessing Biomerica's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Biomerica's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Biomerica's profitability and make more informed investment decisions.
Please note, the presentation of Biomerica's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Biomerica's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Biomerica's management manipulating its earnings.
Evaluate Biomerica's management efficiency
Biomerica has return on total asset (ROA) of (0.3854) % which means that it has lost $0.3854 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7648) %, meaning that it created substantial loss on money invested by shareholders. Biomerica's management efficiency ratios could be used to measure how well Biomerica manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.63. The current year's Return On Capital Employed is expected to grow to -0.86. At present, Biomerica's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Intangible Assets is expected to grow to about 273.3 K, whereas Total Assets are forecasted to decline to about 7.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.39 | 0.37 | |
| Tangible Book Value Per Share | 0.38 | 0.36 | |
| Enterprise Value Over EBITDA | (1.06) | (1.12) | |
| Price Book Value Ratio | 1.48 | 2.30 | |
| Enterprise Value Multiple | (1.06) | (1.12) | |
| Price Fair Value | 1.48 | 2.30 | |
| Enterprise Value | 6.4 M | 9.1 M |
The strategic initiatives led by Biomerica's management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Enterprise Value Revenue 0.8058 | Revenue 5.5 M | Quarterly Revenue Growth 0.055 | Revenue Per Share 0.327 | Return On Equity (0.76) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biomerica insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biomerica's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Biomerica insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Allen Barbieri over three months ago Acquisition by Allen Barbieri of 1538 shares of Biomerica at 2.94 subject to Rule 16b-3 | ||
Allen Barbieri over three months ago Insider Trading | ||
Steven Sloan over six months ago Acquisition by Steven Sloan of 25000 shares of Biomerica at 6.36 subject to Rule 16b-3 | ||
Mark Sirgo over a year ago Acquisition by Mark Sirgo of 25000 shares of Biomerica subject to Rule 16b-3 |
Biomerica Earnings per Share Projection vs Actual
Biomerica Corporate Management
| Hans Boehringer | VP RD | Profile | |
| Steven Sloan | CFO Treasurer | Profile | |
| Lucy Liu | Director Operations | Profile | |
| Robert Carlson | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomerica. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Biomerica Stock refer to our How to Trade Biomerica Stock guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomerica. If investors know Biomerica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomerica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.37) | Revenue Per Share 0.327 | Quarterly Revenue Growth 0.055 | Return On Assets (0.39) | Return On Equity (0.76) |
The market value of Biomerica is measured differently than its book value, which is the value of Biomerica that is recorded on the company's balance sheet. Investors also form their own opinion of Biomerica's value that differs from its market value or its book value, called intrinsic value, which is Biomerica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomerica's market value can be influenced by many factors that don't directly affect Biomerica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomerica's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomerica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomerica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.